Total Payments
$2.2M
2024 Payments
$215,519
Companies
67
Transactions
3,342
Medicare Patients
5,374
Medicare Billing
$12.5M
Payment Breakdown by Category
Other$1.7M (76.5%)
Travel$241,140 (11.0%)
Consulting$196,241 (9.0%)
Food & Beverage$73,144 (3.3%)
Research$3,718 (0.2%)
Education$754.11 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 528 | 70.6% |
| Travel and Lodging | $241,140 | 561 | 11.0% |
| Consulting Fee | $196,241 | 59 | 9.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $74,178 | 49 | 3.4% |
| Food and Beverage | $73,144 | 2,092 | 3.3% |
| Honoraria | $55,607 | 18 | 2.5% |
| Unspecified | $3,718 | 23 | 0.2% |
| Education | $754.11 | 12 | 0.0% |
Payments by Type
General
$2.2M
3,319 transactions
Research
$3,718
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $601,618 | 677 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $304,074 | 512 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $203,557 | 172 | $0 (2024) |
| Biogen, Inc. | $188,596 | 233 | $0 (2024) |
| Genentech USA, Inc. | $176,823 | 188 | $0 (2024) |
| EMD Serono, Inc. | $135,339 | 158 | $0 (2024) |
| Horizon Therapeutics plc | $121,323 | 137 | $0 (2023) |
| TG Therapeutics, Inc. | $96,369 | 92 | $0 (2024) |
| Eisai Inc. | $87,679 | 108 | $0 (2024) |
| Amgen Inc. | $50,120 | 76 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $215,519 | 419 | Eisai Inc. ($78,477) |
| 2023 | $215,639 | 397 | TG Therapeutics, Inc. ($55,553) |
| 2022 | $280,742 | 558 | E.R. Squibb & Sons, L.L.C. ($112,393) |
| 2021 | $134,303 | 343 | Biogen, Inc. ($30,356) |
| 2020 | $122,357 | 227 | Biogen, Inc. ($36,991) |
| 2019 | $439,611 | 477 | GENZYME CORPORATION ($150,682) |
| 2018 | $369,517 | 419 | GENZYME CORPORATION ($168,591) |
| 2017 | $414,620 | 502 | GENZYME CORPORATION ($219,499) |
All Payment Transactions
3,342 individual payment records from CMS Open Payments — Page 1 of 134
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $7.46 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/23/2024 | Amgen Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| 12/19/2024 | Amgen Inc. | UPLIZNA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,300.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/19/2024 | Amgen Inc. | UPLIZNA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/19/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | Cash or cash equivalent | $37.52 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/19/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $6.39 | General |
| Category: Neurology | ||||||
| 12/18/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $20.48 | General |
| Category: Neurology | ||||||
| 12/17/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $28.74 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/16/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | In-kind items and services | $33.56 | General |
| Category: Neurology | ||||||
| 12/16/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $4.49 | General |
| Category: Neuroscience | ||||||
| 12/14/2024 | Cardinal Health Inc | — | Food and Beverage | In-kind items and services | $131.70 | General |
| 12/14/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $29.78 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/13/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $23.47 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $110.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/11/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $28.69 | General |
| Category: Immunology | ||||||
| 12/11/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $7.23 | General |
| 12/10/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $110.59 | General |
| 12/10/2024 | Vanda Pharmaceuticals Inc. | PONVORY (Drug) | Food and Beverage | In-kind items and services | $23.50 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 12/09/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $24.36 | General |
| Category: IMMUNOLOGY | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $839.33 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Travel and Lodging | Cash or cash equivalent | $212.19 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $124.99 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $50.12 | General |
| Category: Neuroscience | ||||||
| 12/06/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $31.39 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis | SANOFI US SERVICES INC. | $2,631 | 14 |
| M14-397 | AbbVie, Inc. | $1,088 | 9 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 1,542 | 87,150 | $10.8M | $3.9M |
| 2022 | 23 | 1,383 | 77,696 | $9.7M | $3.6M |
| 2021 | 22 | 1,282 | 60,247 | $7.6M | $2.8M |
| 2020 | 22 | 1,167 | 49,232 | $6.2M | $2.2M |
Total Patients
5,374
Total Services
274,325
Medicare Billing
$12.5M
Procedure Codes
91
All Medicare Procedures & Services
91 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2023 | 80 | 84,000 | $10.1M | $3.7M | 37.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 174 | 412 | $248,436 | $54,606 | 22.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 96 | 247 | $81,078 | $26,092 | 32.2% |
| G0453 | Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | Facility | 2023 | 42 | 505 | $38,727 | $13,634 | 35.2% |
| 96132 | Evaluation of neuropsychological test, first hour | Office | 2023 | 113 | 114 | $31,920 | $11,302 | 35.4% |
| 95913 | Nerve conduction, 13 or more studies | Office | 2023 | 34 | 34 | $33,150 | $7,971 | 24.0% |
| 96139 | Administration of psychological or neuropsychological test by technician, each additional 30 minutes | Office | 2023 | 114 | 237 | $18,960 | $6,526 | 34.4% |
| 95937 | Testing of nerve-muscle junction | Facility | 2023 | 76 | 200 | $56,400 | $5,741 | 10.2% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 35 | 68 | $23,800 | $5,483 | 23.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 92 | 235 | $24,675 | $5,172 | 21.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 29 | 29 | $24,853 | $4,575 | 18.4% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 12 | 12 | $6,300 | $3,948 | 62.7% |
| 92133 | Imaging of optic nerve | Office | 2023 | 118 | 118 | $41,300 | $3,422 | 8.3% |
| 96138 | Administration of psychological or neuropsychological test by technician, first 30 minutes | Office | 2023 | 113 | 114 | $9,120 | $3,150 | 34.5% |
| 95939 | Placement of skin electrodes and measurement of central motor stimulation in arms and legs | Facility | 2023 | 23 | 23 | $11,868 | $2,175 | 18.3% |
| 51785 | Needle measurement and recording of electrical activity of muscles at bladder and bowel openings | Facility | 2023 | 26 | 26 | $6,682 | $2,122 | 31.8% |
| 95822 | Measurement of brain wave activity (eeg), in coma or asleep | Facility | 2023 | 38 | 38 | $6,796 | $1,803 | 26.5% |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | Office | 2023 | 93 | 442 | $8,623 | $1,787 | 20.7% |
| 95938 | Placement of skin electrodes and measurement of stimulated sites on arms and legs | Facility | 2023 | 37 | 37 | $25,900 | $1,398 | 5.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 13 | 17 | $7,123 | $1,350 | 19.0% |
| 95870 | Needle measurement of electrical activity in arm, leg, trunk or head muscles, limited study | Facility | 2023 | 40 | 80 | $18,000 | $1,307 | 7.3% |
| 95909 | Nerve conduction, 5-6 studies | Facility | 2023 | 16 | 16 | $3,457 | $1,053 | 30.5% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Facility | 2023 | 17 | 33 | $7,425 | $499.12 | 6.7% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2023 | 111 | 113 | $2,825 | $414.58 | 14.7% |
| J2350 | Injection, ocrelizumab, 1 mg | Office | 2022 | 70 | 75,000 | $9.0M | $3.5M | 38.6% |
About Dr. Daniel Becker, MD
Dr. Daniel Becker, MD is a Spinal Cord Injury Medicine healthcare provider based in Lutherville, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2007. The National Provider Identifier (NPI) number assigned to this provider is 1881741775.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Becker, MD has received a total of $2.2M in payments from pharmaceutical and medical device companies, with $215,519 received in 2024. These payments were reported across 3,342 transactions from 67 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.5M).
As a Medicare-enrolled provider, Becker has provided services to 5,374 Medicare beneficiaries, totaling 274,325 services with total Medicare billing of $12.5M. Data is available for 4 years (2020–2023), covering 91 distinct procedure/service records.
Ad
Practice Information
- Specialty Spinal Cord Injury Medicine
- Other Specialties Neurology
- Location Lutherville, MD
- Active Since 01/04/2007
- Last Updated 03/18/2025
- Taxonomy Code 2081P0004X
- Entity Type Individual
- NPI Number 1881741775
Products in Payments
- LEMTRADA (Drug) $354,877
- AUBAGIO (Drug) $236,470
- ZEPOSIA (Drug) $231,919
- GILENYA (Drug) $168,107
- OCREVUS (Biological) $141,782
- UPLIZNA (Drug) $121,280
- TYSABRI (Biological) $101,977
- BRIUMVI (Drug) $90,941
- Leqembi (Drug) $87,359
- MAYZENT (Drug) $84,212
- Mavenclad (Drug) $50,227
- UPLIZNA (Biological) $43,526
- COPAXONE (Drug) $38,420
- Mavenclad (Biological) $33,574
- TECFIDERA (Drug) $32,560
- Ponvory (Drug) $29,887
- AMPYRA (Drug) $29,836
- Non-Covered Product (Drug) $27,397
- MAVENCLAD (Drug) $21,539
- ACTHAR (Biological) $21,389
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.